806 related articles for article (PubMed ID: 33070093)
1. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
2. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.
Wojtuszkiewicz A; Assaraf YG; Maas MJ; Kaspers GJ; Jansen G; Cloos J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):673-89. PubMed ID: 25495223
[TBL] [Abstract][Full Text] [Related]
3. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
5. Biological relevance of alternative splicing in hematologic malignancies.
Szelest M; Giannopoulos K
Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
[TBL] [Abstract][Full Text] [Related]
6. The role of alternative splicing in cancer.
Singh B; Eyras E
Transcription; 2017 Mar; 8(2):91-98. PubMed ID: 28005460
[TBL] [Abstract][Full Text] [Related]
7. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
8. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
9. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
10. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
11. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
12. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
Bessa C; Matos P; Jordan P; Gonçalves V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
Zhang D; Meng F
ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
[TBL] [Abstract][Full Text] [Related]
14. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
16. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
Sahin I; George A; Seyhan AA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
[TBL] [Abstract][Full Text] [Related]
20. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
Dvinge H; Guenthoer J; Porter PL; Bradley RK
Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
